St Joseph's Hospital
London, Ontario, N6A 4V2, Canada
NCT Number: NCT02983318
In a number of neuropsychiatric disorders such as depression, both brain inflammation and glutamate mediated excitotoxicity (cell death through over-activated stimulation) are suspected to play a key role. It is difficult, if not impossible, to determine the potential destructiveness of the inflammatory response seen in disease states by studying the brain's inflammatory cells (microglia) activity in isolation. The investigators are proposing to develop the means to concurrently study inflammatory response (i.e., microglial activity) and its potentially devastating consequence (i.e., glutamate excitotoxicity) across the entire brain in order to establish the importance of inflammation. In this study the investigators propose a phased clinical study whereby the early-phase involves the development of our capacity to study inflammation-mediated damage to brain cells, followed by a feasibility study in patients with clinical depression that tests whether concurrent inflammation and glutamate excess could be measured in key brain regions associated with a depressed mood state.
Looking for future studies?
Notify Me19 year–105 year
All sexes
Observational
London, Ontario, N6A 4V2, Canada
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: single time. Data collected at baseline with no follow up.
Cross sectional MRI/PET scan will be used to identify inflammation related excitotoxicity in the brain in healthy individuals and those diagnosed with major depression.
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Other
Acronym: DiME
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05680727
Behavior, Behavioral Symptoms
Boston, Massachusetts, United States
View Trial DetailsNCT07258485
Depressive Disorder, Depressive Disorder, Major
Phoenix, Arizona, United States
View Trial DetailsNCT06558344
Depressive Disorder, Depressive Disorder, Major
Bellflower, California, United States
View Trial DetailsNCT04533529
Depressive Disorder, Depressive Disorder, Major
Anaheim, California, United States
View Trial Details